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Perspectives of US private payers on insurance coverage for
pediatric and prenatal exome sequencing: Results of a study
from the Program in Prenatal and Pediatric Genomic
Sequencing (P3EGS)
Julia R. Trosman, PhD 1,2, Christine B. Weldon, MBA 1,2, Anne Slavotinek, MD, PhD3,
Mary E. Norton, MD4, Michael P. Douglas, MS1 and Kathryn A. Phillips, PhD 5
Purpose: Exome sequencing (ES) has the potential to improve
management of congenital anomalies and neurodevelopmental
disorders in fetuses, infants, and children. US payers are key
stakeholders in patient access to ES. We examined how payers
view insurance coverage and clinical utility of pediatric and
prenatal ES.
Methods: We employed the framework approach of qualitative
research to conduct this study. The study cohort represented 14
payers collectively covering 170,000,000 enrollees.
Results: Seventy-one percent of payers covered pediatric ES
despite perceived insufficient evidence because they saw merit in
available interventions or in ending the diagnostic odyssey. None
covered prenatal ES, because they saw no merit. For pediatric ES,
50% agreed with expanded aspects of clinical utility (e.g.,
information utility), and 21% considered them sufficient for
coverage. For prenatal ES, payers saw little utility until in utero
interventions become available.
Conclusion: The perceived merit of ES is becoming a factor in
payers’ coverage for serious diseases with available interventions,
even when evidence is perceived insufficient. Payers’ views on ES’s
clinical utility are expanding to include informational utility,
aligning with the views of patients and other stakeholders. Our
findings inform clinical research, patient advocacy, and policy-
making, allowing them to be more relevant to payers.
Genetics in Medicine (2020) 22:283–291; https://doi.org/10.1038/s41436-
019-0650-7
Keywords: exome sequencing; pediatric genetic testing; prenatal
genetic testing; insurance coverage; clinical utility
INTRODUCTION
Congenital anomalies and neurodevelopmental disorders
affect 3–5% of live-born infants and children.1 These
conditions are among the leading causes of infant mortality.2
Life-saving and progression-curbing interventions tailored to
some of these conditions are now available, but many
interventions must be applied expediently, given the possibi-
lity of rapid disease progression.3,4 Accurate and timely
genetic diagnosis is critical, but traditional testing methods,
such as chromosomal microarray (CMA) and single-gene
and/or gene panel tests, produce lower diagnostic rates5 and
may take the patient/family and clinicians on a prolonged
diagnostic odyssey.6,7
Exome sequencing (ES), using next-generation sequencing
technology, offers a broader and more comprehensive
diagnosis of pediatric and prenatal genetic diseases than
tradition testing. Studies have demonstrated that ES diag-
nosed up to 78% of pediatric neurodevelopmental disorders
when other tests did not yield a result8,9 and led to changed
medical management in 30% of diagnosed cases.10 Time-to-
diagnosis advantages have been shown in studies of rapid
genome and/or exome sequencing in the neonatal/pediatric
intensive care unit setting.11,12 ES was also determined to be
more cost-effective than traditional testing.13
As a result, ES is being adopted into clinical practice to
diagnose suspected neurodevelopmental genetic conditions in
children—either in conjunction with CMA or as a first-line
test.14,15 Given the ES diagnostic advantages, it is also being
evaluated for use in the prenatal setting, usually following a
normal CMA result,16 to diagnose ultrasound-detected fetal
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structural anomalies, which affect 2–3% of pregnancies.17
Adding prenatal ES to CMA has been shown to increase the
rate of genetic diagnosis of fetal anomalies, Compared with
standard of care testing.18,19 The increased genetic diagnosis
rate has the potential to improve family counseling and to
inform prenatal and neonatal medical management. However,
at this time, prenatal ES is considered emergent and
experimental, due to the small body of evidence of clinical
benefit and few proven in utero interventions available.16 As
new evidence of ES’s benefit is demonstrated and new fetal
therapies for prenatally detected congenital disorders are
available outside of the research setting, prenatal ES is likely to
become increasingly integrated into clinical practice.
For sustainable clinical adoption in the pediatric and
prenatal settings, ES must be covered by insurance payers.
Although it is possible to receive reimbursement for a novel
genomic technology from a US payer without a formal
positive coverage policy, the absence or variability of formal
positive coverage leads to payment uncertainty, variation in
clinical practice, and barriers to access, particularly for
underserved populations. A study of US payers’ policies has
shown that coverage for pediatric ES increased between 2015
and 2017 but remained fragmented: nearly half of payers
whose policies were reviewed did not formally cover pediatric
ES.20 Prenatal ES is currently not formally covered in the US,
although it is sometimes possible to receive payment. To
facilitate more consistent insurance coverage of pediatric ES,
as well as future coverage for prenatal ES and other novel
genomic tests, it is crucial to understand payers’ coverage
decision-making related to these technologies. This under-
standing is essential to inform researchers developing relevant
evidence, clinicians ordering ES, patient advocacy efforts, and
the work of policy makers.21
The objective of our study was to examine US payers’ views
and perspectives on pediatric and prenatal ES in the context
of coverage decision-making. We focused on the perspective
of private payers because private payers cover two-thirds of
the insured US population.22 The study was conducted at the
University of California–San Francisco (UCSF) within the
Program in Prenatal and Pediatric Genomic Sequencing
(P3EGS). P3EGS is a part of the Clinical Sequencing
Evidence-Generating Research (CSER) consortium, and this
study is aligned with CSER objectives to engage key
stakeholders, including payers.23 This study builds on our
previous research on payer coverage decision-making for
genomics.24–26 These data add to our understanding of payers’
perspectives regarding pediatric and prenatal ES and how
payers view their clinical utility. We focused on clinical utility
because it is a central concept in payers’ coverage decision-
making.25–27 Our findings are significant and timely for
stakeholders not only in pediatric and prenatal ES but also in
other current and future genomic innovations.
MATERIALS AND METHODS
We used the modified framework approach of qualitative
research to design and conduct this semistructured interview
study.28,29 The study was reviewed by the University of
California at San Francisco (UCSF) Institutional Review
Board. The study was classified as exempt under category 2
(Research using educational tests, survey procedures, inter-
view procedures or observation of public behavior), and
verbal consent was obtained of all interviewees.
Study cohort
Study participants were members of the UCSF Center For
Translational and Policy Research on Personalized Medicine
(TRANSPERS) Payer Advisory Council.30 The Council was
established in 2007, and its members have participated in a
number of our previous studies on payer decision-making.24–26
The Council is comprised of senior executives from 14 US
payer entities, including the 8 largest national health plans, 3
major regional health plans, 1 state Medicaid agency, and 2
non–health plan bodies (a multipayer association and a
laboratory benefit management company). Payers participating
in the Council collectively cover over 170,000,000 lives. We
invited all 14 Council members to take part in our study, and
they all participated.
The non–health plan entities were invited because they
develop coverage policies or coverage recommendations for
health plans. For the purposes of this study, we refer to all
participants as payers, to protect the individual and company
anonymity. All participants were decision-makers regarding
coverage for genomic technologies in their respective
organizations: for example, a chief medical officer, a vice
president of medical policy, a head of genetics, and other
senior positions.
Developing the interview guide
To inform the development of the interview guide, we
conducted a literature review and discussions with six clinical
and/or research experts on pediatric and prenatal ES: four
UCSF P3EGS investigators and two outside experts. The
interviews collected their perspectives on the benefits and risks
of pediatric and prenatal ES, with a specific focus on clinical
utility. Experts also suggested questions for payer interviews
that would be of interest to clinicians and researchers.
Based on literature review and expert input, we developed a
semistructured interview guide. The guide included interview
questions (see Table 1 for an excerpt), as well as background
and context, such as a description of the standard of care
testing for congenital anomalies and neurodevelopmental
disorders and the role of ES in management of these
conditions. The interview questions asked about the level of
interest in prenatal and pediatric ES, the reasons that payers
covered or did not cover these technologies, how they
perceived risks of ES in these settings, and what they thought
about suggestions provided by experts on how to facilitate
coverage of pediatric and prenatal ES (see Table 1).
In addition, the interview guide contained background and
questions related to the clinical utility of pediatric and prenatal
ES. To frame these questions, we reviewed definitions of the
clinical utility of genomic tests in the literature. The debate
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over how to define clinical utility is ongoing, and numerous
definitions have been proposed.31,32 They vary in breadth (e.g.,
whether it is improvement in health outcomes, or also the
ability to diagnose and/or change clinical management), and in
scope (e.g., whether it pertains only to the patient tested, or
also to the family). To explore payers’ perspectives, we
followed the recommendation by the American College of
Medical Genetics and Genomics (ACMG) to expand the
framing of clinical utility to a broader, multifaceted view of
clinical utility for genomics.33 We used a definition adapted
from ACMG: clinical utility of genetic testing is a continuum
of benefits, which encompasses a spectrum of aspects,
including the value of a diagnosis to the individual and
family, as well as effects on diagnostic or therapeutic
management, and implications for prognosis, health, and
physiological benefits to patients and their relatives.
Guided by this definition, and informed by discussions with
experts, we conceptualized clinical utility for pediatric and
prenatal ES in two diagrams (Figs. 1 and 2), which were
included with the interview guide. One of the interview
Table 1 Interview semistructured questions
1. What is the level of interest in pediatric and prenatal ES in your organization, relative to other medical technologies or services?
• What are the reasons for this level of interest?
2. Do you currently cover ES (or recommend coverage for ES, if you are not a payer) in pediatric setting? In prenatal setting?
• Why/why not?
3. What is your opinion on the aspects of clinical utility of pediatric ES (Fig. 1) and prenatal ES (Fig. 2)?
• Do you agree/disagree with the aspects of clinical utility depicted? Why agree/disagree?
• In each diagram, which aspect(s) alone would be sufficient for coverage, in the absence of other aspects?
4. What do you perceive the risks and challenges of ES in pediatric and prenatal settings to be?
5. What is your reaction to the these suggestions by clinical experts on how to provide insurance coverage for pediatric and prenatal ES:
• Consider pediatric and prenatal ES research as clinical practice, because in reality, patients receive ES in the research as clinical care.
• Base reimbursement for ES on a limited number of qualified institutions with demonstrated high quality of relevant care.
This table presents an excerpt from the interview guide. The guide also included background and context (description of standard of care testing for congenital anoma-
lies and neurodevelopmental disorders and the role of ES in management of these conditions), as well as Figs. 1 and 2 conceptualizing clinical utility.
ES exome sequencing.
Testing
Suspicion of
genetic
condition
Microarray
testing ES
ES may be used
before microarray
Genetic disease
found
Rule-out of
known genetic
disease
End of diagnostic odyssey
Diagnosis
Intervention:
Curative
Slowing disease progression and/or
Managing symptoms/complications
Utility for family care:
Parents’ reproductive decisions
Diagnoses for family members with
suspected genetic conditions
Withdrawal of futile interventions,
and/or transition to palliative care
Informational utility:
directing family to disease-specific
support, education, research
Management
and outcomes
Pursuing other diagnostics and/or
interventions, e.g. consider
environmental factors
Child
care
Fig. 1 Aspects of clinical utility of pediatric exome sequencing. Boxes corresponding to aspects of clinical utility are shaded. ES exome sequencing.
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questions explored whether payers agreed with the various
aspects of clinical utility conceptualized in the diagrams and
whether these aspects were independently sufficient for
granting coverage to pediatric and/or prenatal ES.
Data collection and analysis
Semistructured interviews were conducted with the study
cohort from January through April 2019. The interviews were
conducted over the phone; they lasted 45–60 minutes each,
were recorded, with interviewee’s verbal consent, and later
transcribed verbatim for analyses. Interviewees received the
study description and the interview guide in advance. They
were promised that all results would be reported in an
unattributable, anonymous, and aggregate fashion. No inter-
viewees were offered or received payment for participation.
Two investigators (J.R.T., C.B.W.) conducted thematic
analyses and coding of the transcribed interviews. Disagree-
ments were resolved by discussion and consensus. Simple
frequencies were used to further describe the findings.
RESULTS
Payers’ interest in and coverage of pediatric and prenatal ES
Considerably more payers reported high or medium interest
in pediatric than prenatal ES (Table 2). Cited reasons for high
and medium interest in pediatric ES were significant test
implications, both positive and negative; the serious nature of
relevant conditions; and cost concerns driven by high test
prices and increasing usage of pediatric ES. Payers with low
interest explained it by insufficient demand from their
physician networks, the perception that ES is not ready for
clinical practice, and competing internal priorities related to
genetic testing, such as cancer genetics.
Most payers in our cohort noted that their organizations
provided (or recommended) coverage for pediatric ES (71%,
10/14), while none covered prenatal ES (Table 2). Payers
covering pediatric ES found evidence of its clinical utility
insufficient but recognized the merit of the test (i.e., saw the
overall underlying need for it). The merit for pediatric ES was
based on its potential to inform the available clinical
interventions (70%, 7/10) or to end the diagnostic odyssey
(30%, 3/10). However, half of the payers covering pediatric ES
still expressed concerns about potential inappropriate use,
expanding indications, and difficulty interpreting test results.
Hence, they established limitations on covered clinical scenarios
and ordering specialties, and some have implemented prior
authorization and utilization management programs.
In contrast to pediatric ES, where payers saw some, albeit
insufficient evidence, they found no evidence of clinical utility
for prenatal ES, and some of them doubted the ability to
generate enough evidence in the future. Also, the majority saw
Testing
ES
Utility for family care:
Parents’ reproductive decisions
Diagnoses for family members with
suspected genetic conditions
ES may be used
before microarray
Obtaining genetic diagnosis
prenatally
Microarray
testing
Structural
anomalies on
sonogram;
suspicion of
genetic
disease
Diagnosis
Fetus/child care
In utero intervention*
Referral to tertiary center for delivery
and specialized medical
management of newborn
Termination decision
informed by ES
Upon birth, withdrawal of futile
interventions, and/or provision of
palliative care only
Informational utility: directing family
to disease-specific support,
education, research
Management
and outcomes
Fig. 2 Aspects of clinical utility of prenatal exome sequencing. Boxes corresponding to aspects of clinical utility are shaded. ES exome sequencing.
*Few in utero nontermination interventions are currently available outside of research setting.
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no merit in its use, explaining that the lack of in utero
interventions outside of research settings obviated the need to
perform ES in the prenatal versus postnatal setting, where
interventions are available. Thus, in their opinions, ES added
no informational value above prenatal ultrasound and
standard genetic testing.
How payers viewed clinical utility of pediatric and
prenatal ES
The obtained insights regarding clinical utility are summar-
ized in Table 3 and described below. The interviews assessed
two angles: whether payers agreed with a specific aspect of
ES’s clinical utility (Table 3, column 2), and whether they
considered this aspect independently sufficient for coverage if
other aspects are absent and/or unproven (Table 3, column 3).
Pediatric ES
Payers viewed aspects of the clinical utility of pediatric ES
relative to the current standard of testing. All payers agreed
that from a coverage perspective, the incremental impact on
clinical outcomes for pediatric patients tested with ES versus
standard is the most desirable aspect of clinical utility.
However, a sizable minority (43%, 6/14) considered a change
in clinical management and/or another aspect of clinical
utility as acceptable and sufficient for coverage (Table 3).
While 64% (9/14) of payers perceived withdrawal of futile
interventions as a valid component of clinical utility, only 36%
(5/14) viewed it as independent and stand-alone. Others
commented that this aspect is secondary to outcome
improvement and change in interventions, and therefore
should not be used independently to demonstrate the utility
of a genetic test. As one interviewee stated: “I hope we are not
using genetics to discontinue care for patients. I would not
encourage that this sort of treatment futility is demonstrated
through a genetic test.”
Similarly, 50% (7/14) of payers acknowledged the informa-
tional utility of ES (directing family to disease-specific
support, education, and research), but most regarded
informational utility as secondary to other aspects of clinical
utility. Only three payers considered informational utility as
potentially sufficient for coverage if evidence demonstrated an
impact on patient care. None of the payers regarded utility for
family care—reproductive decisions or diagnosis for siblings
—as independently sufficient for coverage. They commented
that “supporting or informing the family is not the primary
reason to use ES—these should be linked to other aspects. For
example, a support group is important for parents when
stopping futile care or transferring to hospice.”
The end of the diagnostic odyssey was viewed by most
payers (64%, 9/14) as a valid aspect of clinical utility, and
several of them considered it sufficient for coverage (Table 3).
These payers agreed with Fig. 1 that the end of the diagnostic
odyssey is different from informational utility, in that it stops
further genetic testing and may inform disease-specific
medical management. However, of these nine payers, only
two agreed that receiving a negative result may, in fact, end
the diagnostic odyssey. Others noted that “on the surface, the
rule-out utility makes sense, but only if we can resolve the
challenge of VUS (variants of unknown significance) or
inaccurate results, which may result in additional work that
could be unnecessary or harmful.”
Prenatal ES
Here, payers discussed clinical utility not only relative to
standard testing but also compared with testing ES after
birth. Overall, 79% (11/14) of payers expressed difficulty
recognizing the clinical utility of prenatal ES, in the absence
of proven in utero clinical interventions. Consequently, they
viewed other aspects of clinical utility in Fig. 2 as secondary
and not relevant until in utero interventions become
available in clinical practice. All interviewed payers stated
that they would not consider pregnancy termination as an
intervention or an aspect of clinical utility in the context of
coverage policy. Provided reasons included regulatory,
political, and/or ethical challenges, and skepticism that a
genetic diagnosis adds to the termination decision beyond
sonographic results.
Table 2 Interest in and coverage of pediatric and prenatal
exome sequencing by the payer cohort
% of payers
Level of overall interest in ES, N= 14
Pediatric ES
High 57% (8/14)
Medium 29% (4/14)
Low 14% (2/14)
Prenatal ES
High 29% (4/14)
Medium 21% (3/14)
Low 50% (7/14)
Currently provide coverage (or recommend coverage if you are a
nonpayer)? N= 14
Pediatric ES 71% (10/14)
Prenatal ES 0% (0/14)
Reasons for coverage of pediatric ES, N= 10
Availability of interventions informed by ES 70% (7/10)
See value in ending “the diagnostic odyssey” 30% (3/10)
Reasons for noncoverage of pediatric ES, N= 4
Insufficient evidence of utility of ES vs. standard care 75% (3/4)
See no merit in any multigene testing, including ES 25% (1/4)
Reasons for noncoverage of prenatal ES, N= 14
No evidence of utility 100% (14/14)
See no merit of ES prenatally, vs. postnatallya 79% (11/14)
Skeptical about the ability to gather evidencea 29% (3/14)
See more harm than benefita 14% (2/14)
High interest: actively follow new studies, frequent internal review of coverage
and/or new indications. Medium interest: occasional review of new studies, some-
what frequent review of coverage. Low interest: not following new studies, infre-
quent or no internal discussions of coverage and/or new indications.
ES exome sequencing
aNot mutually exclusive.
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Likewise, most payers expressed skepticism that prenatal ES
and an in utero genetic diagnosis provide any incremental
value compared with sonography and CMA testing. Accord-
ingly, 57% (8/14) of payers thought that referral to a tertiary
center for delivery and specialized newborn management
should happen anyway, based on abnormal ultrasound
results. All payers described other aspects of clinical utility
(informing withdrawal of futile interventions, informational
utility, and utility for parents’ reproductive decisions) as
occurring after birth, and therefore relevant to the pediatric
but not prenatal clinical utility of ES (Table 3). Several payers
noted that availability of rapid sequencing made a timely
diagnosis after birth feasible and obviated the necessity for
prenatal ES. One payer added that in exceptional circum-
stances, ES may be performed several weeks before birth, to
prepare for the immediate neonatal intervention.
Payers’ opinions on potential risks and harms of pediatric
and prenatal ES
All interviewed payers argued that considerations of clinical
utility include not only potential benefits of ES but also
potential risks and harms. Each payer expressed several
concerns of risks and harms, including the impact of VUS on
additional testing, care, and costs; VUS-related anxiety for
families and clinicians; difficulty interpreting ES results;
accuracy of ES; uncertainty of how to handle secondary
genetic findings; and psychological trauma of genetic
diagnosis for parents. Payers believed that the risks and
harms were higher in the prenatal setting, where the absence
of clinical interventions and the inability to phenotypically
examine the baby add to the uncertainty of diagnosis and
management and elevate parents’ stress. This was one of
the reasons they saw higher net utility for pediatric than
prenatal ES.
Payers’ responses to experts’ suggestions for insurance
coverage of pediatric and prenatal ES
In preparing the interview guide, experts made two sugges-
tions for expanding insurance coverage of pediatric ES and
establishing coverage for prenatal ES. First, they suggested
that for rare serious conditions, such as pediatric congenital
anomalies and neurodevelopmental disorders, the research
setting is the only one available for patients to receive clinical
care; therefore, payers should consider covering ES as part of
this care. In the interviews, 21% (3/14) of payers agreed that
research in these settings could be considered clinical practice
because of the very rare conditions and high disease burden.
However, they noted regulatory and business challenges in
providing insurance coverage in research settings. Other
payers did not agree with this suggestion because covering
research would contradict their mission and contractual
obligations to employers and enrollees. They also noted that it
would be challenging to decide which research settings,
diseases, and modalities should or should not be covered.
Second, experts suggested coverage of pediatric and
prenatal ES only when ordered by selected tertiary centers
with specialized resources able to interpret results and provide
adequate care. A slight majority of payers (57%, 8/14) agreed
that this approach could be effective and appropriate for
pediatric and prenatal ES. They described similar approaches
in managing other rare and complex conditions, such as
organ transplant, by developing a network of centers of
excellence. Nevertheless, they stated challenges associated
with such programs: establishing clear criteria, quality
metrics, and standards for participating centers, and addres-
sing the needs of patients in remote locations from tertiary
centers. Several payers, both affiliated and not affiliated with
Blue Cross Blue Shield, shared that they were considering
such networks for complex modalities such as ES.
Table 3 Payers’ views on aspects of clinical utility for pediatric and prenatal exome sequencing
% of payers who agree with
this aspect of utility, N= 14
% of payers who agree that this aspect
is sufficient for clinical utility, N= 14
Pediatric ESa
Health outcomes of clinical interventions informed by ESa 100% (14/14) 100% (14/14)
Change in clinical interventions informed by ESa 100% (14/14) 43% (6/14)
Withdrawal of futile interventions, and/or transition to palliative care 64% (9/14) 36% (5/14)
End of diagnostic odyssey (negative result: rule-out, or positive result: genetic
diagnosis)
64% (9/14) 21% (3/14)
Informational utility: directing family to disease-specific support, education,
research
50% (7/14) 21% (3/14)
Utility for family care: parents’ reproductive decisions; diagnoses for family
members with suspected genetic conditions
50% (7/14) 0%
Prenatal ESb
Referral to tertiary center for delivery and specialized medical management of
newborn
43% (6/14) 21% (3/14)
Termination decision, informed by ES 0% 0%
Upon birth, withdrawal of futile interventions, and/or provision of palliative
care only
0% 0%
Obtaining genetic diagnosis prenatally 29% (4/14) 0%
Informational utility: directing family to disease-specific support, education,
research
0% 0%
Utility for family care: parents’ reproductive decisions; diagnoses for family
members with suspected genetic conditions
0% 0%
ES exome sequencing.
aCompared with current standard of care diagnostics in pediatric setting.
bCompared with current standard of care diagnosis in in prenatal setting, and to ES postbirth.
ARTICLE TROSMAN et al
288 Volume 22 | Number 2 | February 2020 | GENETICS in MEDICINE
DISCUSSION
This study examined perspectives of a cohort of US payers
on insurance coverage for pediatric and prenatal ES for
congenital anomalies and neurodevelopmental disorders.
We found that 71% of the payer cohort covers pediatric ES,
despite perceived insufficient evidence, because they see
merit in available interventions or in ending the diagnostic
odyssey. None of them covered prenatal ES, primarily
because they saw no merit in prenatal versus postnatal ES
(79%). Our study also examined how payers viewed an
expanded spectrum of clinical utility for ES, beyond the
impact on clinical outcomes and management. For pediatric
ES, at least 50% agreed with expanded aspects of clinical
utility, including ending diagnostic odyssey, informational
utility (directing family to disease-specific support, educa-
tion, and research) or family utility for reproductive
decision-making. Moreover, 21% considered ending the
diagnostic odyssey and informational utility independently
sufficient for coverage. None of the payers viewed informa-
tion utility as a compelling aspect of clinical utility
prenatally until in utero interventions are available in
clinical practice.
Previous studies explored payers’ views on other genomic
tests, including those in cancer and pharmacogenomics.24–26,34
They found that while payers use a range of considerations
in coverage decision-making, sufficient evidence of clinical
utility was a central and necessary factor for coverage. In
contrast, we found that for pediatric neurodevelopmental
disorders and congenital anomalies, the perceived merit of ES
was a key factor in coverage, despite perceptions of insufficient
clinical evidence. This finding suggests that payers’ perception
of merit is a concept that should be further studied to
understand how it is shaped, if/how it applies to other clinical
areas, and how it relates to other coverage decision-making
factors.
Consistent with previous studies, payers in our cohort
consider the impact on clinical outcomes and management
as primary aspects of clinical utility. However, unlike prior
studies, our findings indicate that payers are open to
accepting expanded aspects of clinical utility, notably
diagnostic and informational utility, for settings with
available clinical interventions, such as pediatric neurode-
velopmental disorders. Personal and family information
utility has been deemed important by medical societies who
urged their inclusion in the scope of the clinical utility of
genomics.33,35 It has also been shown of value to parents of
children with rare genetic disorders undergoing exome
sequencing.7 Our findings imply that payers’ views on the
clinical utility of genomic sequencing are evolving toward
higher congruence with those of other constituencies.
Our study may have implications for a range of stake-
holders in the field of genomic sequencing, including
clinicians, researchers, patient advocates, policy makers, and
payers themselves. Our results inform the efforts of
researchers studying established and emergent applications
of ES to produce evidence of clinical utility relevant to payers
and other audiences. One such effort is the UCSF P3EGS
program, under which this study was conducted. P3EGS is a
part of the CSER consortium and is aimed at investigating
clinical utility for pediatric and prenatal ES.36 Although many
payers cover pediatric ES, coverage varies across payers and
often has limited indications.20 By generating evidence of
clinical utility relevant to payers’ expectations, P3EGS and
other investigators could help facilitate broader and more
consistent coverage. Likewise, for emerging sequencing tests,
such as prenatal ES, payers’ perspectives on clinical utility in
the context of available interventions could help design
relevant studies, as well as shape broader research priorities,
focused on developing interventions in clinical areas where
they are lacking.
Our study may be instructive to patient advocates, policy
makers, and others aiming to improve equitable access to
genomic technologies, particularly for underrepresented and
minority patients. Understanding how payers evaluate these
technologies may inform advocacy and policy work and
potentially make it more effective. We also believe that the
expanded conceptualization of clinical utility for ES developed
in this study could be applied to other clinical areas and used
to facilitate dialogues with a broader range of stakeholders.
We plan to pursue this avenue by examining clinical utility
from the broader perspective across CSER sites and
stakeholders, and working with the Clinical Utility, Health
Economics, and Policy (CUHEP) working group formed
within the CSER consortium.37
As the genomic field is likely to transition from exome to
genome sequencing,38 understanding payers’ coverage con-
siderations will become increasingly important. Genome
sequencing may exacerbate payers’ concerns about merit
and utility in various diseases, and the risks and harms from
VUS. This and future studies on payer decision-making will
help to frame a cohesive and proactive research, advocacy,
and policy agenda for integrating genomic sequencing into
coverage policy, reimbursement, and clinical practice.
Our study had several limitations. We used a relatively
small cohort of payers, although collectively, their policies
affect over 170 million enrollees. Public payers who cover
substantial numbers of underserved and minority populations
were underrepresented in our cohort. Medicaid is especially
relevant to coverage for pediatric and prenatal disorders, but
we were unable to broadly examine Medicaid policy decision-
making in this study. Engaging Medicaid and other public
payers in direct interview studies has been a challenge for
researchers. Public multistakeholder forums organized by
quasi-government bodies such as the National Academy of
Medicine may be a more feasible mechanism to elucidate their
insight on coverage for sequencing technologies. Finally, some
experts recommend encompassing cost-effectiveness as an
aspect of the clinical utility of genomic testing. We did not
include cost-related aspects in the scope of our study. Future
research should elucidate whether and how payers consider
cost-effectiveness as an aspect of clinical utility in coverage
decisions.
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Conclusions
We examined the views of US payers on insurance coverage
and clinical utility of exome sequencing (ES) for congenital
anomalies and neurodevelopmental disorders in pediatric and
prenatal settings. We found that the perceived merit of ES is
becoming a factor in payers’ coverage for serious diseases,
such as pediatric neurodevelopmental disorders, with avail-
able interventions, even when payers consider clinical
evidence insufficient. We also found that payers’ perspectives
on ES are evolving to include expanded aspects of clinical
utility, notably information utility. This may indicate a trend
toward higher congruence of payers’ perspectives with those
of patients and other stakeholders. Future research should
elucidate payers’ views on expanded clinical utility for exome
and genome sequencing across diseases. Our findings inform
clinical research, patient advocacy, and policy-making,
allowing their efforts to be more relevant in a dialogue with
payers.
SUPPLEMENTARY INFORMATION
The online version of this article (https://doi.org/10.1038/s41436-
019-0650-7) contains supplementary material, which is available
to authorized users.
ACKNOWLEDGEMENTS
This study was funded by grants from the National Human
Genome Research Institute (U01 HG009599) and National Cancer
Institute (R01 CA221870).
DISCLOSURE
K.A.P. and M.P.D. receives consulting income from Illumina, Inc.,
M.E.N. receives grant support from Natera and is a consultant to
Invitae. The other authors declare no conflicts of interest.
Publisher’s note Springer Nature remains neutral with regard
to jurisdictional claims in published maps and institutional
affiliations.
REFERENCES
1. Feldkamp ML, Carey JC, Byrne JLB, Krikov S, Botto LD. Etiology and
clinical presentation of birth defects: population based study. BMJ.
2017;357:j2249.
2. Mone F, Quinlan-Jones E, Ewer AK, Kilby MD. Exome sequencing in the
assessment of congenital malformations in the fetus and neonate. Arch
Dis Child Fetal Neonatal Ed. 2019;104:F452–F456.
3. Soden SE, Saunders CJ, Willig LK, et al. Effectiveness of exome and
genome sequencing guided by acuity of illness for diagnosis of
neurodevelopmental disorders. Sci Transl Med. 2014;6:265ra168.
4. Willig LK, Petrikin JE, Smith LD, et al. Whole-genome sequencing for
identification of Mendelian disorders in critically ill infants: a retrospective
analysis of diagnostic and clinical findings. Lancet Respir Med. 2015;
3:377–387.
5. Clark MM, Stark Z, Farnaes L, et al. Meta-analysis of the diagnostic and
clinical utility of genome and exome sequencing and chromosomal
microarray in children with suspected genetic diseases. NPJ Genom Med.
2018;3:16.
6. Lewis C, Skirton H, Jones R. Living without a diagnosis: the parental
experience. Genet Test Mol Biomarkers. 2010;14:807–815.
7. Marshall DA, MacDonald KV, Heidenreich S, et al. The value of diagnostic
testing for parents of children with rare genetic diseases. Genet Med.
2019 Jun 26; https://doi.org/10.1038/s41436-019-0583-1 [Epub ahead
of print].
8. Vissers L, van Nimwegen KJM, Schieving JH, et al. A clinical utility study of
exome sequencing versus conventional genetic testing in pediatric
neurology. Genet Med. 2017;19:1055–1063.
9. Niguidula N, Alamillo C, Shahmirzadi Mowlavi L, Powis Z, Cohen JS,
Farwell Hagman KD. Clinical whole-exome sequencing results impact
medical management. Mol Genet Genomic Med. 2018;6:1068–1078.
10. Stark Z, Tan TY, Chong B, et al. A prospective evaluation of whole-exome
sequencing as a first-tier molecular test in infants with suspected
monogenic disorders. Genet Med. 2016;18:1090–1096.
11. Petrikin JE, Cakici JA, Clark MM, et al. The NSIGHT1-randomized
controlled trial: rapid whole-genome sequencing for accelerated etiologic
diagnosis in critically ill infants. NPJ Genom Med. 2018;3:6.
12. Mestek-Boukhibar L, Clement E, Jones WD, et al. Rapid Paediatric
Sequencing (RaPS): comprehensive real-life workflow for rapid diagnosis
of critically ill children. J Med Genet. 2018;55:721–728.
13. Stark Z, Schofield D, Alam K, et al. Prospective comparison of the cost-
effectiveness of clinical whole-exome sequencing with that of usual care
overwhelmingly supports early use and reimbursement. Genet Med.
2017;19:867–874.
14. Iglesias A, Anyane-Yeboa K, Wynn J, et al. The usefulness of whole-
exome sequencing in routine clinical practice. Genet Med. 2014;
16:922–931.
15. Rexach J, Lee H, Martinez-Agosto JA, Nemeth AH, Fogel BL. Clinical
application of next-generation sequencing to the practice of neurology.
Lancet Neurol. 2019;18:492–503.
16. Jelin AC, Vora N. Whole exome sequencing: applications in prenatal
genetics. Obstet Gynecol Clin North Am. 2018;45:69–81.
17. Centers for Disease Control and Prevention (CDC). Update on overall
prevalence of major birth defects–Atlanta, Georgia, 1978–2005. MMWR
Morb Mortal Wkly Rep. 2008;57:1–5.
18. Lord J, McMullan DJ, Eberhardt RY, et al. Prenatal exome sequencing
analysis in fetal structural anomalies detected by ultrasonography (PAGE):
a cohort study. Lancet. 2019;393:747–757.
19. Petrovski S, Aggarwal V, Giordano JL, et al. Whole-exome sequencing in
the evaluation of fetal structural anomalies: a prospective cohort study.
Lancet. 2019;393:758–767.
20. Douglas MP, Parker SL, Trosman JR, Slavotinek AM, Phillips KA.
Private payer coverage policies for exome sequencing (ES) in pediatric
patients: trends over time and analysis of evidence cited. Genet Med.
2019;21:152–160.
21. Deverka PA, Kaufman D, McGuire AL. Overcoming the reimbursement
barriers for clinical sequencing. JAMA. 2014;312:1857–1858.
22. United States Census Bureau. Health insurance coverage in the United
States: 2017. https://www.census.gov/library/publications/2018/demo/
p60-264.html. Accessed 15 July 2019.
23. Amendola LM, Berg JS, Horowitz CR, et al. The Clinical Sequencing
Evidence-Generating Research Consortium: integrating genomic
sequencing in diverse and medically underserved populations. Am J
Hum Genet. 2018;103:319–327.
24. Trosman JR, Van Bebber SL, Phillips KA. Coverage policy development for
personalized medicine: private payer perspectives on developing policy
for the 21-gene assay. J Oncol Pract. 2010;6:238–242.
25. Trosman JR, Weldon CB, Kelley RK, Phillips KA. Challenges of coverage
policy development for next-generation tumor sequencing panels:
experts and payers weigh in. J Natl Compr Canc Netw. 2015;
13:311–318.
26. Trosman JR, Weldon CB, Douglas MP, et al. Payer coverage for hereditary
cancer panels: barriers, opportunities, and implications for the Precision
Medicine Initiative. J Natl Compr Canc Netw. 2017;15:219–228.
27. Pezalla EJ. Payer view of personalized medicine. Am J Health Syst Pharm.
2016;73:2007–2012.
28. Ritchie J, Lewis J. Qualitative research practice: a guide for social science
students and researchers. Thousand Oaks, CA: Sage Publications; 2003.
29. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the
framework method for the analysis of qualitative data in multi-disciplinary
health research. BMC Med Res Methodol. 2013;13:117.
30. UCSF Center for Translational and Policy Research onPersonalized
Medicine (TRANSPERS). Evidence and reimbursement for personalized
medicine program. https://pharm.ucsf.edu/transpers/grants-programs/
evidence-reimbursement. Accessed 15 July 2019.
31. Grosse SD, Khoury MJ. What is the clinical utility of genetic testing?
Genet Med. 2006;8:448–450.
32. Burke W, Laberge AM, Press N. Debating clinical utility. Public Health
Genomics. 2010;13:215–223.
ARTICLE TROSMAN et al
290 Volume 22 | Number 2 | February 2020 | GENETICS in MEDICINE
33. ACMG Board of Directors. Clinical utility of genetic and genomic services:
a position statement of the American College of Medical Genetics and
Genomics. Genet Med. 2015;17:505–507.
34. Keeling NJ, Rosenthal MM, West-Strum D, Patel AS, Haidar CE, Hoffman
JM. Preemptive pharmacogenetic testing: exploring the knowledge and
perspectives of US payers. Genet Med. 2019;21:1224–1232.
35. Joseph L, Cankovic M, Caughron S, et al. The spectrum of clinical utilities
in molecular pathology testing procedures for inherited conditions and
cancer: a report of the Association for Molecular Pathology. J Mol Diagn.
2016;18:605–619.
36. Clinical Sequencing Evidence-Generating Research (CSER). Prenatal and
Pediatric Genome Sequencing (P3EGS). https://cser-consortium.org/
projects/4073. Accessed 30 July 2019.
37. National Human Genome Research Institute. Clinical Sequencing
Evidence-Generating Research (CSER). https://www.genome.gov/
Funded-Programs-Projects/Clinical-Sequencing-Evidence-Generating-
Research-CSER2. Accessed 10 July 2019.
38. Prokop JW, May T, Strong K, et al. Genome sequencing in the clinic: the
past, present, and future of genomic medicine. Physiol Genomics.
2018;50:563–579.
TROSMAN et al ARTICLE
GENETICS in MEDICINE | Volume 22 | Number 2 | February 2020 291
